logo
Plus   Neg
Share
Email

AbbVie : Late-stage Plaque Psoriasis Study Meets Primary & Secondary Endpoints

AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks.

Of patients treated with skyrizi, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks. At week 16, skyrizi also met the other primary endpoint of non-inferiority to Cosentyx with 74 percent of skyrizi patients achieving PASI 90 compared to 66 percent of Cosentyx patients.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CJ Foods, Inc., a division of CJ America, Inc., recalled Annie Chun's Japanese-Style Teriyaki Noodle Bowls due to undeclared peanuts, the U.S. Food and Drug Administration said. The La Palma, California-based company initiated the recall after discovering that some bowls that were packaged in outer sleeves indicating Teriyaki Noodle Bowls contain Pad Thai noodle, which contains peanuts. Struggling home furnishings retailer Pier 1 Imports, Inc. said it filed for Chapter 11 bankruptcy protection as it is initiating a sale process. The company is in discussions with multiple potential buyers. In a statement, the company said it has also entered into a Plan Support Agreement or PSA with a majority of its term loan lenders. The deadline to submit bids will be on or around March 23. Apple Inc. (AAPL) said it doesn't expect to meet its revenue guidance for the second quarter due to lower smartphone demand, and temporary work slowdowns related to coronavirus outbreak in China.
Follow RTT
>